Why Is PALVELLA THERAPEUTIC (PVLA) Stock Up Today?

PVLA stock rose 15.94% to $143.94 in the session, driven by H.C. Wainwright reiterating its Buy rating for Palvella Therapeutics. The stock opened at $144.50 and has traded flat throughout the session. The move follows recent regulatory progress in the company’s drug development pipeline.

What Happened

H.C. Wainwright reaffirmed its Buy rating for Palvella Therapeutics, signaling continued confidence in the company’s strategic direction and pipeline. The stock has seen a sharp intraday increase, opening at $144.50 and maintaining that level throughout the session. While the stock has traded within a narrow range, the move reflects investor reaction to the analyst rating and recent developments in the company’s regulatory process.

Palvella Therapeutics has submitted the first module of its rolling New Drug Application (NDA) to the FDA for QTORIN 3.9% Rapamycin Anhydrous Gel, intended for the treatment of Microcystic Lymphatic Malformations. The FDA has also initiated a rolling review of the application. Earlier, the company completed a Pre-NDA meeting with the FDA and remains on track to submit the full NDA in the second half of 2026. Additionally, Palvella received a U.S. patent for its licensed QTORIN Pitavastatin program for Porokeratosis.

What The Data Shows

PVLA has a market capitalization of $2.3 billion but remains unprofitable, with a trailing twelve-month earnings per share (EPS) of -4.19. The stock has traded between $29.59 and $161.38 over the past 52 weeks. The current session has seen no trading volume so far, with the stock opening and remaining at $144.50. Over the past 30 days, investor sentiment has improved, rising from an average of 57 out of 100 to 64 out of 100 in the last seven days.

What To Watch

The company’s progress with the QTORIN NDA submission and FDA review will be key to monitor in the coming months. Investors should also watch for any changes in analyst coverage or regulatory updates that could impact the stock’s trajectory.